Literature DB >> 19514966

Clinical pharmacology and pharmacogenetics of gemcitabine.

Andrea Wong1, Ross A Soo, Wei-Peng Yong, Federico Innocenti.   

Abstract

Gemcitabine is a cytotoxic nucleoside analog, which is widely used in the treatment of malignancies. Interindividual differences in gemcitabine pharmacokinetics and pharmacodynamics have been demonstrated. Pharmacogenetic factors may account for a significant proportion of these differences. This review provides an update on the pharmacogenetics of gemcitabine and its influence on gemcitabine efficacy and toxicity.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19514966     DOI： 10.1080/03602530902741828

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN： 0360-2532            Impact factor:   4.518


  52 in total

Review 1.  The role of transporters in the toxicity of nucleoside and nucleotide analogs.

Authors:  Christopher A Koczor; Rebecca A Torres; William Lewis
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-04-18       Impact factor: 4.481

2.  Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.

Authors:  Milena Gusella; Felice Pasini; Caterina Bolzonella; Silvia Meneghetti; Carmen Barile; Antonio Bononi; Silvia Toso; Daniela Menon; Giorgio Crepaldi; Yasmina Modena; Laura Stievano; Roberto Padrini
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

3.  Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment.

Authors:  Daniel Braas; Ethan Ahler; Brenna Tam; David Nathanson; Mirielle Riedinger; Matthias R Benz; Kathleen B Smith; Fritz C Eilber; Owen N Witte; William D Tap; Hong Wu; Heather R Christofk
Journal:  Cancer Discov       Date:  2012-12       Impact factor: 39.397

4.  N-acetyl-L-cysteine sensitizes pancreatic cancers to gemcitabine by targeting the NFκB pathway.

Authors:  Suparna Qanungo; Joachim D Uys; Yefim Manevich; Anne M Distler; Brooke Shaner; Elizabeth G Hill; John J Mieyal; John J Lemasters; Danyelle M Townsend; Anna-Liisa Nieminen
Journal:  Biomed Pharmacother       Date:  2014-08-28       Impact factor: 6.529

5.  Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts.

Authors:  Xu Zhu; Sheryl Trueman; Robert M Straubinger; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-08-01       Impact factor: 2.745

6.  CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.

Authors:  Yangzom D Bhutia; Sau Wai Hung; Bhavi Patel; Dylan Lovin; Rajgopal Govindarajan
Journal:  Cancer Res       Date:  2011-02-22       Impact factor: 12.701

7.  Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation.

Authors:  Beata Hryciuk; Bartosz Szymanowski; Anna Romanowska; Ewa Salt; Bartosz Wasąg; Bartłomiej Grala; Jacek Jassem; Renata Duchnowska
Journal:  Oncol Lett       Date:  2017-11-22       Impact factor: 2.967

8.  Molecular predictors of gemcitabine response in pancreatic cancer.

Authors:  Ioannis A Voutsadakis
Journal:  World J Gastrointest Oncol       Date:  2011-11-15

9.  Moving away from candidate genes: a 'genome-wise' discovery of gemcitabine myelotoxicity.

Authors:  Federico Innocenti
Journal:  Pharmacogenomics       Date:  2012-07       Impact factor: 2.533

10.  Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.

Authors:  Xu Zhu; Robert M Straubinger; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-08       Impact factor: 2.745
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.